143 related articles for article (PubMed ID: 36933395)
1. Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into β-position to the carboxylic acid.
Chen C; Guo SM; Sun Y; Li H; Hu N; Yao K; Ni H; Xia Z; Xu B; Xie X; Long YQ
Eur J Med Chem; 2023 May; 251():115267. PubMed ID: 36933395
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
3. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
[TBL] [Abstract][Full Text] [Related]
4. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
Chen C; Li H; Long YQ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
[TBL] [Abstract][Full Text] [Related]
5. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
Rani L; Grewal AS; Sharma N; Singh S
Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
[TBL] [Abstract][Full Text] [Related]
6. GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.
Mohammad S
Curr Drug Targets; 2016; 17(11):1292-300. PubMed ID: 26648068
[TBL] [Abstract][Full Text] [Related]
7. Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.
Guo B; Guo S; Huang J; Li J; Li J; Chen Q; Zhou X; Xie X; Yang Y
Bioorg Med Chem; 2018 Dec; 26(22):5780-5791. PubMed ID: 30392954
[TBL] [Abstract][Full Text] [Related]
8. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
Negoro N; Sasaki S; Mikami S; Ito M; Suzuki M; Tsujihata Y; Ito R; Harada A; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Kogame A; Matsunaga S; Yasuma T; Momose Y
ACS Med Chem Lett; 2010 Sep; 1(6):290-4. PubMed ID: 24900210
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
[TBL] [Abstract][Full Text] [Related]
11. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.
Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J
Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709
[TBL] [Abstract][Full Text] [Related]
13. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.
Araki T; Hirayama M; Hiroi S; Kaku K
Diabetes Obes Metab; 2012 Mar; 14(3):271-8. PubMed ID: 22051148
[TBL] [Abstract][Full Text] [Related]
14. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
Burant CF
Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S175-9. PubMed ID: 23882043
[TBL] [Abstract][Full Text] [Related]
15. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.
Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Zhou C; Lin S; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger JP; Mills SG; Thornberry NA; Yang L; Howard AD
Diabetes; 2008 Aug; 57(8):2211-9. PubMed ID: 18477808
[TBL] [Abstract][Full Text] [Related]
16. GPR40-Mediated G
Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
[TBL] [Abstract][Full Text] [Related]
17. GPR40: a therapeutic target for mediating insulin secretion (review).
Feng XT; Leng J; Xie Z; Li SL; Zhao W; Tang QL
Int J Mol Med; 2012 Dec; 30(6):1261-6. PubMed ID: 23023155
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.
Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M
J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170
[TBL] [Abstract][Full Text] [Related]
19. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
[TBL] [Abstract][Full Text] [Related]
20. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.
Tanaka H; Yoshida S; Minoura H; Negoro K; Shimaya A; Shimokawa T; Shibasaki M
Life Sci; 2014 Jan; 94(2):115-21. PubMed ID: 24269216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
